Two clinical case histories are presented that indicate that naive ingestion of the anorectic, phenylpropanolamine, may induce psychotic reactions in patients with preexisting diagnosed psychiatric disturbance. These clinical observations and concerns are buttressed by a review of the scientific literature relevant to the psychotic inducing effects of phenylpropanolamine and structurally similar sympathomimetic derivatives of P-phenylethylamine, such as amphetamine and ephedrine.
INTRODUCTION
wo CLINICAL CASE HISTORIES ARE REPORTED here that, in view of other published work, provide T substantial evidence that phenylpropanolamine (PPA) may induce psychotic reactions in unsuspecting people, for example, those taking PPA medication as anorectics or nasal decongestants. A noteworthy observation is that people with a prior history of psychiatric disturbance may be particularly susceptible to this untoward effect of PPA.
PPA is structurally similar to amphetamine, ephedrine, and other sympathomimetic derivatives of P-phenylethylamine. Amphetamine is well recognized as having the capability of producing psychotic reactions. Kiloh and Brandon(4) state that often even psychiatrists have not recognized the frequency of amphetamine psychoses and often misdiagnose such cases. Weh~er'~' indicates that mentally ill patients are especially susceptible to the psychotic-inducing effects of amphetamine. However, psychotic reactions can be elicited in anyone by prolonged exposure in sufficient quantities. Ephedrine, although less potent than amphetamine, has precautions similar to those for amphetamine in its use as a sympathomimetic drug, The structural similarities among amphetamine, ephedrine, and PPA are clear. Dieti9 notes that, like these sympathomimetic amines, the centrally acting norepinephrine and dopamine also lack a methyl group on the nitrogen and that this feature enhances the potential for PPA to exert its effects. W e i~~e r '~) has reported that, in contrast to catecholamines, most of the clinically used methyl phenylethylamines not bearing hydroxyl substituents on the benzene nucleus are effective when given orally and may act for long periods. Methyl phenylethylamines (including amphetamine, soon after their administration and are found in high concentrations in the brain and cerebrospinal fluid, in contrast to catecholamines, which cross the blood-brain barrier with difficulty. Also, according to the work of Weiner, amphetamine and ephedrine are resistant to the action of monamine oxidase (MAO) and inhibit the action of this enzyme toward other substances. D' MeU"' ) reported that PPA is also not a substrate for MAO, thus establishing another similarity between amphetamine and PPA.
The central action of amphetamine is generally attributed to increases in concentration of norepinephrine (NE) or dopamine (DA) in the synaptic cleft,(*,') induced either by blockade of reuptake of these amines or by stimulation of release or both. These effects can be blocked by phenothiazines, butyrophenones, and lithium. (s) In reviewing the subject of the role of catecholamines in paranoid schizophrenia, Snyder") indicates that since amphetamine psychosis has often been mistaken for paranoid schizophrenia and since both conditions uniquely respond to treatment with phenothiazines, both may in some way be due to disturbances in the brain DA system.
Phenothiazines, which are selectively antischizophrenic, are also potent antidotes in amphetamine psychoses.('o) Angrist et al.(") have reported that haloperidol (a neuroleptic), a specific blocker of DA, is effective in antagonizing amphetamine-induced symptoms. Snyder'') cites others in noting that phenothiazines alter DA metabolism in a manner indicating that they block DA receptors in the brain.
Thus, if schizophrenia and amphetamine psychoses have the common characteristic of increased concentration of DA in the synaptic cleft and phenothiazines block the action of DA at the DA receptor, benefit from phenothiazine treatment in both cases would be consistent with the proposed common etiology. If it can be shown that PPA, like amphetamine, increases DA concentrations, promotes the characteristic amphetamine reactions in animals, and is antagonized by phenothiazines, a potential for this substance to promote psychotic reactions is established at fundamental molecular and pharmacological levels, which would support clinical observations of PPA-induced psychotic reactions.
In behavioral testing, Zelger and Carlini(121 were able to show that PPA will produce ipsilateral circling in rats in which lesions of the substantia nigra have been induced by intracerebral injection of 6-hydro~ydopamine."~) Such behavior in this experimental model is considered to reflect the degree of dopamine receptor stimulation and is highly reproducible. In this study, amphetamine was observed to be more potent and of shorter maximum onset time than was phenylpropanolamine.
However, the action of PPA on this behavioral response was much more sustained than that of amphetamine. When observed for a total of 240 minutes, the PPA effect declined much less sharply than that of amphetamine. In in vitro studies, amphetamine and PPA inhibited the uptake and enhanced the release of DA. The ICs0 for amphetamine was 6 x lo-' M and that of PPA, 2.5 x lo+ M with respect to inhibition of uptake of DA in rat striatal slices. Thus, in both well-characterized behavioral and in vitro biochemical studies, PPA exhibited the same kind of fundamental activity as amphetamine.
The behavioral study enables us to speculate that amphetamine, although slightly more potent than PPA, is more rapidly metabolized and eliminated. Thus, consequent to repeated administrations at dosages equivalent to those commonly used for amphetamine, there may be more potential for PPA to bioaccumulate, reaching concentrations in tissues where the more dramatic adverse effects of amphetamine might be observed.
RELEVANT CLINICAL LITERATURE
Several investigations have reported an association between PPA ingestion and amphetamine-like psychotic reactions. (6.11.'4-20) I n some of these studies, psychotic reactions occurred consequent to overdosage of PPA; however, in others, psychotic reactions were observed after administration of normal doses of PPA-containing medication during treatment of such conditions as otitis and respi-ratory infections. Kane and Green"6' reported psychotic reactions as being observed even in the presumably well-controlled hospital setting, suggesting inadequate medical awareness of this potential complication. The related compound, ephedrine, has also been reported to be associated with psychotic reactionsfs.z1.22) and to exacerbate an underlying schizophrenic illness. (W CASE REPORT 1 S. is a tl-year-old white female who at the age of 16 was hospitalized for several months because of disruptive behavior, including sexual promiscuity, running away from home, poor school performance, and excessive use of alcohol and marijuana.
One year later, the patient suffered a severe psychotic breakdown, requiring 2 months of hospitalization during which she displayed active psychotic symptoms. A diagnosis of schizophrenic illness was made at this time, and the patient responded to doses of up to 30 mg of haloperidol (Haldol).
Three years ago, the patient came for outpatient treatment, with symptomatology centered around marked withdrawal and secretiveness. Much of the time'in the initial year of psychotherapy, the patient remained silent except for inappropriate, nonsensical outbursts. When it was learned that her father had been successfully treated for paranoid thinking with trifluoperazine (Stelazine), the patient's medication was changed to trifluoperazine, 20 mg, contihuing since then in the range of 10 to 20 mg per day. During the past year, there has been marked improvement, with the patient able to break the dependent ties on her family, becoming more autonomous, and functioning without overwhelming and paralyzing anxiety. During the 6 months before this 3-year period of observation, the patient exhibited no signs of psychosis, and because of this marked improvement, her medication at that time had been reduced to a maintenance level of 5 mg daily of Haldol.
At this point, the patient, in an effort to lose weight, purchased over-the-counter medication that contained 75 mg of PPA. After 6 days of self-administration, she returned for consultation in a markedly agitated state. Her pulse rate was 92, and she complained of headaches across the frontal area and reported that the feeling was somewhat similar to that which she had when taking amphetamines. Her behavior was markedly inappropriate, and her mood was labile, fluctuating between intense anxiety and simple laughter. There was evidence of paranoid thinking, including such vocal expressions as, "My roommate is out to do me in."
The trifluoperazine was increased to 30 mg per day, and the patient was advised to discontinue the PPA and return to her parents' house rather than be hospitalized. Within the next few days, the symptoms thought to be associated with self-administration of PPA disappeared, and the patient was once again stabiIized.
CASE REPORT 2
K. is a 23-year-old white, married female with one child, who had been hospitalized following a psychotic breakdown . The patient had become preoccupied with forces and had active auditory and visual hallucinations and marked paranoid ideations. There were lesions from razor slashes on her upper arm, self-administered as punishment for 6er evil thoughts. After 3 weeks in the hospital, she was discharged and instructed to take 10 mg of haloperidol per day and to return for psychotherapy. After 6 months of a comparatively stable period, the patient reported extreme anxiety, inability to care for her child, and a preoccupation with idiosyncratic thoughts. During an interview, she revealed that she had been taking a diet preparation containing 75 mg of PPA for several days. This preparation was discontinued, and within 3 days, there was a marked reduction of anxiety and psychotic thought processes. No further antipsychotic medication was thought necessary, and for the ensuing 5 months, there has been no evidence of deterioration.
DISCUSSION
Two clinical cases have been presented that illustrate an association between PPA ingestion and the development of psychoses. It is interesting that regression of the first patient after more recent ingestion of PPA was different in character than her previous psychotic regressions over the past 3 years. The previous pattern was marked by withdrawal and autistic preoccupation, whereas the psychosis after ingestion of PPA was characterized by a paranoid anxiety and, by the patient's own report, mimicked the results of experimenting with amphetamine.
In support of the assertion that PPA induced the psychotic reactions in these two patients are the many reports of similar clinical observations associated with this drug.
People with existing or prior mental illness may be particularly susceptible to the adverse effects of PPA, as has been observed with amphetamine. (2.3.5) Biochemical studies indicate that amphetamine and PPA behave similarly and that PPA, although less potent, has greater potential to bioaccumulate, thus posing an enhanced threat with repeated consumption. Janowski et al.,('O) in work with methylphenidate, proposed a concept of psychosis activation as opposed to psychosis induction in explaining adverse reactions to this drug. Methylphenidate, an analog of amphetamine and PPA, administered to schizophrenic patients during the active phase of illness w i l l activate psychotic symptoms, whereas it will not produce this effect in the same patients after remission has occurred. Segal and J a n o w~k i '~~) indicate that low doses of methylphenidate (0.5 mglkg) cause psychosis activation rather than psychosis induction, which is well known to occur at high doses. A principal observation is that psychosis activationintensification of preexisting psychotic symptomsoccurs in patient abnormalities, such as schizophrenia, schizophrenia in partial remission, and manic-depressive disorder, whereas normal persons, schizophrenics in remission, and patients with nonpsychotic problems do not so respond. In contrast to the ability of antipsychotic drugs, such as chlorpromazine to antagonize psychostimulant-induced psychoses, such drugs do not block this activation phenomenon, suggesting differing mechanisms of action.
Regardless of the mechanism involved, however, much evidence supports the view that patients with psychotic illnesses are peculiarly subject to the untoward effects of PPA, and, hence, psychiatrists should advise and prescribe for patients accordingly.
